BioSpace News Archive

Real Time Medical Systems (Real Time), the leading healthcare interventional analytics software company for long-term care facilities, hospitals, ACOs, and payers, has seen a 150% growth in sales since the beginning of 2018 as demand increases for an intuitive Patient-Driven Payment Model (PDPM) solution amongst SNFs nationwide.

This month, the non-profit Medical Education Institute (MEI) celebrates 15 years of raising awareness and use of peritoneal dialysis and home hemodialysis through Home Dialysis Central, which launched on July 1, 2004.

At the 61st American Association of Physicists in Medicine (AAPM) Annual Meeting & Exhibition, July 14 - 18 in San Antonio, Elekta (EKTA-B.ST) will feature advanced quality assurance (QA) and treatment planning solutions that simplify the delivery of radiation therapy techniques.

The First World Longevity Forum and Life Science Conference (WLF&LSC), organized by Hezhou Municipal People’s Government, opened on Friday in Hezhou city, south China’s Guangxi Zhuang Autonomous Region.

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that its collaborator Janssen Biotech, Inc. (Janssen) has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for the subcutaneous delivery of DARZALEX® (daratumumab) for patients with multiple myeloma.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a new subcutaneous (SC) formulation of DARZALEX® (daratumumab), an intravenous (IV) treatment approved for certain patients with multiple myeloma.

Dante Labs today introduced a new artificial intelligence (AI) tool to create personalized reports from whole genome sequencing data that leverages a person’s medical information to identify the most relevant insights across the six billion letters that make up human DNA.

Results showed that treatment with Emgality, when compared to placebo, resulted in lower levels of migraine-related disability and fewer restrictions on daily activities that are limited by migraine, such as relationships with family and friends, leisure time, productivity, concentration, energy and fatigue

New clinical trial marks third study underway with neflamapimod in neurodegenerative disease

Schrödinger announced receipt of a milestone payment from Ono Pharmaceutical Co., Ltd. as part of a collaboration leveraging Schrödinger’s advanced computational platform to develop novel therapeutic candidates acting on the therapeutic target selected by Ono.